age-related macular degeneration
Ophthalmology · 2007–2025
7decisions
3medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| aflibercept Biosimilar to Eylea for intravitreal injection; same indications as the reference biologic aflibercept (Eylea). | Jul 2025 | Recommended with restriction | none received |
| aflibercept Sub-foveal choroidal neovascularisation secondary to age-related macular degeneration (neovascular age-related macular degeneration; nAMD). | Nov 2024 | Recommended with restriction | none received |
| brolucizumab Treatment of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD). | Nov 2019 | Not recommended | input received Macular Disease Foundation Australia |
| aflibercept Initial and continuing treatment by an ophthalmologist, as the sole PBS-subsidised therapy, of subfoveal choroidal neovascularisation (CNV) due to age-related… | Mar 2012 | Recommended with restriction | unclear |
| aflibercept Initial and continuing treatment of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD) in treatment-naïve patients. | Mar 2012 | Recommended with restriction | unclear |
| ranibizumab treatment of subfoveal choroidal neovascularisation (CNV) due to age related macular degeneration (AMD) | Mar 2007 | Recommended with restriction | no section in document |
| ranibizumab Treatment of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD), including predominantly classic, minimally classic,… | Mar 2007 | Recommended with restriction | no section in document |
Who spoke
Macular Disease Foundation Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.